Evidence map›Paper›PMID 40869366›Full record

ReviewInternational journal of molecular sciences2025

Unraveling the Converging Roles of ASC-Dependent Inflammasomes, Interleukin-1 Superfamily Members, Serum Amyloid A, and Non-Sterile Inflammation in Disease Pathology and Fibrosis in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Marco Losa, Marlene Schwarzfischer, Marc Emmenegger, Marianne R Spalinger, Gerhard Rogler, Michael Scharl

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marco LosaDepartment of Gastroenterology and Hepatology, University Hospital Zurich, 8091 Zurich, Switzerland.ORCID 0000-0003-3428-418X
Marlene SchwarzfischerDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zürich, 8006 Zurich, Switzerland.ORCID 0000-0003-1288-0706
Marc EmmeneggerDivision of Medical Immunology, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0002-6073-8811
Marianne R SpalingerDepartment of Gastroenterology and Hepatology, University Hospital Zurich, 8091 Zurich, Switzerland.ORCID 0000-0003-4498-0058
Gerhard RoglerDepartment of Gastroenterology and Hepatology, University Hospital Zurich, 8091 Zurich, Switzerland.ORCID 0000-0002-1733-9188
Michael ScharlDepartment of Gastroenterology and Hepatology, University Hospital Zurich, 8091 Zurich, Switzerland.

Funding

UZH Postdoc Grant FK-25-049
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC) are chronic immune-mediated inflammatory diseases (IMIDs) that affect the gastrointestinal and hepatobiliary systems. They are characterized by persistent inflammation, potentially progressive fibrosis, and an elevated risk of developing cholangiocarcinoma and colorectal cancer. IBD and PSC share phenotypical, genetic, and immunological features, largely due to the central role of immune cell dysregulation. Despite their increasing global prevalence, the underlying drivers remain poorly understood, and effective treatment options are still lacking. Efforts towards an improved comprehension of their pathogenic mechanisms are therefore pivotal. Emerging evidence highlights the role of canonical ASC-dependent inflammasomes-multiprotein bioactive Interleukin (IL)-1-producing complexes of the innate immune system-and serum amyloid A (SAA) as key structures of gastrointestinal and hepatobiliary inflammation, tissue remodeling, stromal crosstalk, and fibrosis. In this review, we explore immunological connections and analogies between IBD and PSC, highlighting the converging roles of canonical ASC-dependent inflammasomes, the IL-1 superfamily, SAA, and sustained gut microbiota-driven chronic inflammation in disease pathology and their surging potential as therapeutic targets across the gut-liver axis.

Indexed as

CARD Signaling Adaptor ProteinsCholangitis, SclerosingInflammasomesInflammatory Bowel DiseasesInterleukin-1Serum Amyloid A ProteinAnimalsFibrosisGastrointestinal MicrobiomeHumansInflammationCARD Signaling Adaptor ProteinsInflammasomesInterleukin-1Serum Amyloid A Proteinapoptosis-associated speck-like protein containing a caspase recruitment domain (ASC)caspase-1caspase recruitment domain (CARD)chronic inflammationfibrosisgut microbiomeIL-1IL-18IL-1 receptor(R)1IL-33inflammasome adapterinflammasomesinflammatory bowel disease (IBD)innate immunityInterleukin (IL)-1 superfamilyintestinal microbesnon-sterile inflammationprimary sclerosing cholangitis (PSC)pyrin domain (PYD)serum amyloid A (SAA)therapeutic agents

Identifiers

PMID40869366
PMCPMC12386582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.